Akash Tewari
Stock Analyst at Jefferies
(2.12)
# 2,832
Out of 4,786 analysts
59
Total ratings
36.36%
Success rate
-4.37%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $63 → $70 | $60.99 | +14.77% | 3 | Dec 16, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $70.69 | +34.39% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $91.06 | +64.73% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $2.62 | +510.69% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $110.60 | +70.89% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $21.87 | +265.80% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $30.17 | +148.59% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $825.91 | +22.89% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $33.02 | +51.42% | 6 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $37.36 | +100.75% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $16.14 | +92.13% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $32 → $40 | $7.02 | +469.80% | 2 | Dec 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $634.23 | +47.74% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $2.47 | +385.83% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.34 | +53.91% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $5.52 | +226.09% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $591.87 | -13.32% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.76 | +552.17% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $89.76 | +39.26% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $11.91 | -7.64% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $3.47 | +3.75% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $2.03 | +737.44% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $40.19 | +86.61% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $331.23 | -54.41% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $36.92 | -24.16% | 3 | Oct 7, 2021 | |
Bristol-Myers Squibb Company
Dec 16, 2024
Upgrades: Buy
Price Target: $63 → $70
Current: $60.99
Upside: +14.77%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $70.69
Upside: +34.39%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $91.06
Upside: +64.73%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $2.62
Upside: +510.69%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $110.60
Upside: +70.89%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $21.87
Upside: +265.80%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $30.17
Upside: +148.59%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $825.91
Upside: +22.89%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $33.02
Upside: +51.42%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $37.36
Upside: +100.75%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $16.14
Upside: +92.13%
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $7.02
Upside: +469.80%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $634.23
Upside: +47.74%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $2.47
Upside: +385.83%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.34
Upside: +53.91%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $5.52
Upside: +226.09%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $591.87
Upside: -13.32%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $2.76
Upside: +552.17%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $89.76
Upside: +39.26%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $11.91
Upside: -7.64%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $3.47
Upside: +3.75%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $2.03
Upside: +737.44%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $40.19
Upside: +86.61%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $331.23
Upside: -54.41%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $36.92
Upside: -24.16%